One targets the fat you can't see. The other drops the number on the scale. Different tools, different jobs.
Bottom line: Semaglutide produces dramatic total weight loss (15-22%). Tesamorelin specifically reduces visceral fat (15-18%) while the scale barely moves. If your goal is metabolic health and body composition, tesamorelin is the precision tool. If your goal is losing weight, semaglutide is the proven sledgehammer. Some people run both.
| Tesamorelin | Semaglutide | |
|---|---|---|
| What it actually is | GHRH (growth hormone-releasing hormone) analog. FDA-approved as Egrifta for HIV-associated lipodystrophy. Tells your pituitary to release GH in a natural burst-and-fade pattern. | GLP-1 receptor agonist. FDA-approved as Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral). Mimics a gut hormone that tells your brain you're full. |
| Mechanism | Stimulates pituitary GH release. The GH signal mobilizes visceral fat for oxidation while leaving subcutaneous fat alone. Does not suppress appetite. Does not reduce caloric intake. | Activates GLP-1 receptors in the brain and gut. Suppresses appetite, slows gastric emptying, and reduces food intake. The caloric deficit drives total body weight loss across all fat compartments. |
| What fat it targets | Visceral fat specifically. The deep, organ-wrapping fat you can't pinch. Subcutaneous fat is not meaningfully affected. The scale barely moves but imaging shows the dangerous fat shrinking. | All fat compartments. Visceral, subcutaneous, and lean mass all decrease proportionally. The scale moves dramatically. Visceral fat drops about 40% as part of total weight loss. |
| Weight loss (trial data) | Minimal. Scale weight barely changed in Phase 3 trials. The effect is body composition, not weight loss. Don't expect the number to move. | 14.9% at 68 weeks (STEP 1, 2.4mg). 20.7% at 72 weeks with the investigational 7.2mg dose (STEP UP). Dramatic, visible, measurable. |
| Visceral fat reduction | 15.4% at 26 weeks, 17.5% at 52 weeks (Phase 3 pooled). Selective: only visceral stores targeted. | ~40% reduction in visceral fat as part of overall weight loss (STEP 1 imaging substudy). Non-selective: comes with loss of subcutaneous fat and lean mass too. |
| Dose | 2mg subcutaneous daily (FDA-approved). Compounded versions often start at 1mg. No titration needed. Flat dose from day one. | 0.25mg weekly, titrated up over 16+ weeks to 2.4mg weekly. Rushing the titration is the number one mistake. Slow and steady. |
| Injection frequency | Once daily, evening preferred. 30 pins per month. | Once weekly, any time. 4 pins per month. Oral option (Rybelsus) for zero pins. |
| Effect on appetite | None. Tesamorelin does not suppress hunger or change eating behavior. You eat the same amount. | Profound. Food noise stops. People describe suddenly not thinking about food. This is the primary driver of weight loss. |
| Effect on muscle | Preserves and may slightly increase lean mass. GH and IGF-1 are anabolic. Meta-analysis showed +1.42 kg lean body mass. | Reduces lean mass alongside fat. Roughly 39% of weight lost in STEP trials was lean mass. Resistance training and high protein intake are essential to mitigate this. |
| Top side effects | Injection-site reactions (35%). Joint pain (15%). Water retention (10%). Muscle aches (8%). All GH class effects, usually resolve by week 3-4. | Nausea (44%). Diarrhea (30%). Constipation (24%). Vomiting (24%). GI events peak at each dose increase and usually fade. |
| Cardiovascular data | Improved triglycerides as a secondary endpoint in Phase 3 trials. No dedicated cardiovascular outcomes trial. | SELECT trial: 20% MACE reduction in 17,604 patients with obesity and CVD. The gold standard. |
| Liver fat data | 37% hepatic fat reduction (Stanley et al.). Direct GH-mediated lipolysis in liver tissue. Improved ALT/AST. | Improves liver fat via overall weight loss. No dedicated liver fat trial, but real-world data shows meaningful hepatic improvement. |
| FDA approval | Egrifta / Egrifta SV (HIV-associated lipodystrophy, 2010). Not approved for general obesity. EMA withdrew application in 2012. | Ozempic (T2D, 2017), Wegovy (obesity, 2021), Rybelsus (oral T2D, 2019). The broadest approval profile of any weight-loss compound. |
| Monthly cost (approx.) | ~$1,200-1,800/month through prescribing clinics. No widely available low-cost compounded option. | Branded Wegovy ~$1,349/month. Compounded (where available) ~$150-300/month. |
| What happens when you stop | Visceral fat returns toward baseline within ~24 weeks. Tesamorelin stimulates GH pulses; the effect stops when the signal stops. | Weight regains approximately two-thirds within one year (STEP 1 extension). The appetite suppression stops and eating patterns return. |
tierA: {"tier":1,"label":"FDA-approved, completed Phase 3"}
tierB: {"tier":1,"label":"FDA-approved, completed Phase 3"}
summary: Both are FDA-approved with completed Phase 3 programs. Semaglutide has the largest evidence base of any weight-loss compound: STEP 1-5 trials, the 17,604-patient SELECT cardiovascular outcomes trial, and millions of real-world patients. Tesamorelin has two Phase 3 RCTs in 806 patients, FDA approval since 2010, and a separate NAFLD trial showing liver fat reduction. The EMA declined approval in 2012 citing insufficient evidence of clinical meaningfulness beyond fat reduction itself.
trials: [{"name":"Tesamorelin Phase 3 pooled analysis (HIV lipodystrophy)","peptide":"a","n":"806","finding":"2mg/day SubQ for 26 weeks reduced visceral fat by 15.4% vs +0.6% placebo. At 52 weeks, visceral fat reduction sustained at 17.5%. Subcutaneous fat was not significantly affected.","pmid":"20554713","citation":"Falutz J et al. J Clin Endocrinol Metab. 2010."},{"name":"Tesamorelin hepatic fat reduction","peptide":"a","n":"61","finding":"37% hepatic fat reduction in HIV patients with NAFLD. Visceral fat reduction was independently associated with improved liver enzymes (ALT, AST).","pmid":"22495074","citation":"Stanley TL et al. Clin Infect Dis. 2012."},{"name":"Tesamorelin GH secretion in lipodystrophy","peptide":"a","n":"30","finding":"Growth hormone secretion was lower in men with HIV lipodystrophy than comparison groups. Higher visceral fat was associated with lower GH output, establishing the mechanistic rationale.","pmid":"11158000","citation":"Rietschel P et al. J Clin Endocrinol Metab. 2001."},{"name":"Tesamorelin early dose-finding (2mg)","peptide":"a","n":"61","finding":"The 2mg dose reduced trunk fat and improved visceral-to-subcutaneous fat ratio. Visceral fat fell 15.7% but did not reach significance vs placebo in this smaller trial.","pmid":"16052083","citation":"Falutz J et al. J Acquir Immune Defic Syndr. 2005."},{"name":"STEP 1 (semaglutide 2.4mg, obesity)","peptide":"b","n":"1961","finding":"14.9% mean body weight loss vs 2.4% placebo at 68 weeks. In the subset with CT imaging, visceral fat decreased approximately 40% alongside the total weight loss.","pmid":"33567185","citation":"Wilding JPH et al. N Engl J Med. 2021."},{"name":"SELECT (semaglutide cardiovascular outcomes)","peptide":"b","n":"17604","finding":"20% reduction in major adverse cardiovascular events (MACE) in patients with obesity and established CVD but no diabetes. The largest cardiovascular outcomes trial for any weight-loss compound.","pmid":"37952131","citation":"Lincoff AM et al. N Engl J Med. 2023."},{"name":"Real-world visceral fat comparison (2026 meta-analysis)","peptide":"both","n":"meta","finding":"Tesamorelin reduced visceral adipose tissue by 27.71 cm2 vs placebo. Semaglutide reduced visceral fat by approximately 40% as part of total weight loss. The mechanisms differ: semaglutide shrinks everything via caloric deficit; tesamorelin selectively mobilizes visceral stores via GH-mediated lipolysis.","pmid":null,"citation":"2026 pooled analysis across multiple RCTs."}]
{"applies":true,"name":"Tesamorelin + Semaglutide","intro":"The combination makes pharmacological sense. Semaglutide handles appetite suppression and total weight loss through the GLP-1 pathway. Tesamorelin handles visceral fat targeting and lean mass preservation through the GH pathway. Different mechanisms, complementary effects. Some longevity and metabolic clinics prescribe both for patients who want aggressive body composition optimization without sacrificing muscle.","phases":[{"name":"GLP-1 base","detail":"Semaglutide at prescribed dose, weekly injection, titrated per standard protocol"},{"name":"Tesamorelin add-on","detail":"1-2mg tesamorelin daily, evening, subcutaneous in abdomen. Added once GLP-1 dose is stable (usually after 8+ weeks of titration)"}],"note":"No RCT has studied this combination. The rationale is mechanistic, not trial-validated. The cost is significant ($1,500+/month combined). The benefit is full-spectrum fat loss: GLP-1 reduces total weight and appetite; tesamorelin selectively mobilizes visceral stores and protects lean mass. Monitor IGF-1 and fasting glucose. The GH from tesamorelin is insulin-antagonistic, and semaglutide improves insulin sensitivity, so they partially offset each other on glucose."}
No. Tesamorelin does not suppress appetite, reduce caloric intake, or produce meaningful scale weight change. It specifically reduces visceral fat through growth hormone signaling. If you want the number on the scale to go down, semaglutide is the tool. They solve different problems.
Yes, substantially. The STEP 1 imaging substudy showed approximately 40% visceral fat reduction alongside total weight loss. But semaglutide reduces all fat compartments and lean mass proportionally. It's not selective. Tesamorelin specifically targets visceral stores while leaving subcutaneous fat and muscle alone.
Some clinicians prescribe both together. The mechanisms are complementary: semaglutide suppresses appetite and drives overall weight loss; tesamorelin targets visceral fat and preserves lean mass. No RCT has studied this combination. The cost is high ($1,500+/month). If you run both, monitor IGF-1 and fasting glucose because tesamorelin raises GH (insulin-antagonistic) while semaglutide improves insulin sensitivity.
Three reasons. First, tesamorelin is approved only for HIV-associated lipodystrophy, not general obesity. Semaglutide is approved for everyone with a BMI over 27+. Second, tesamorelin requires daily injections vs weekly for semaglutide. Third, tesamorelin costs $1,200-1,800/month through prescribing clinics, while compounded semaglutide runs $150-300/month. The barrier is access and cost, not effectiveness.
Tesamorelin. It elevates GH and IGF-1, which are anabolic. The 2026 meta-analysis showed +1.42 kg lean body mass gain on tesamorelin. Semaglutide causes lean mass loss (roughly 39% of total weight lost). If muscle preservation is your priority, tesamorelin has the better profile. But even on tesamorelin, resistance training matters.
Both improve liver fat, but through different mechanisms. Tesamorelin has a dedicated study showing 37% hepatic fat reduction via direct GH-mediated lipolysis in liver tissue. Semaglutide improves liver fat as part of overall weight loss. If fatty liver is the primary concern and your weight is otherwise stable, tesamorelin has the more specific evidence. If you also need to lose significant weight, semaglutide covers both.
The European Medicines Agency reviewed the same Phase 3 data and found the visceral fat reduction was not demonstrated to be 'clinically meaningful' in terms of actual health outcomes like cardiovascular events or mortality. They also flagged IGF-1 elevation as a safety concern without long-term data. The application was withdrawn in June 2012 before a formal rejection vote. The FDA approved it with IGF-1 monitoring as a requirement.
It comes back. Visceral fat returns toward baseline within approximately 24 weeks of stopping. The same is true for semaglutide: weight regains about two-thirds within a year. Neither drug produces permanent changes. They work while you take them.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
